Ceftriaxone is a new semisynthetic cephalosporin with broad-spectrum in vitro activity and an unusually long serum half-life. The clinical efficacy of ceftriaxone was evaluated in 35 infections in 34 patients; 12 of these patients had skin and soft tissue infections, 10 had infections of the urinary tract, 8 had pneumonia, 2 had biliary tract infections, 1 had sinusitis, 1 had diverticulitis, and 1 had a retroperitoneal abscess. Of the 35 infections, 9 were bacteremic. The bacteria isolated included Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus faecalis, other streptococcal species, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Serratia marcescens, Enterobacter cloacae, Haemophilus influenzae, Pseudomonas aeruginosa, Bacteroides fragilis, other Bacteroides species, and anaerobic cocci. Improvement or cure occurred in 32 episodes, for a response rate of 91%. There were three treatment failures in patients with soft tissue infections. No serious drug toxicities were observed. At a dosage regimen of 1 g every 12 h the peak and trough serum antibiotic concentrations were well above the minimal inhibitory concentrations of most pathogens. Our findings suggest that ceftriaxone is a safe and effective antibiotic for therapy of serious bacterial infections.
Ceftriaxone is a new semisynthetic 3-lactam antibiotic with excellent antimicrobial activity against most gram-positive and gram-negative bacteria, including Pseudomonas aeruginosa (1, 2, 4, 7, 9) . The broad in vitro spectrum of ceftriaxone suggests that this agent may provide adequate therapy against most bacterial infections. Furthermore, the long serum half-life of 6.5 to 8.6 h indicates that this drug can be given less frequently than conventional agents (3, 6, 8 The clinical response was evaluated for each documented infection in patients who received at least 72 h of ceftriaxone therapy. Cure was defined as resolution of systemic and local signs of infection, accompanied by elimination of the pathogen from cultures of the original site of infection. Improvement was defined as the occurrence of two of the following: (i) resolution of fever, (ii) elimination of the pathogen from the infected site, or (iii) disappearance of local signs of infection. Patients in whom urinary tract infections were eradicated while they were receiving ceftriaxone but who were placed on subsequent antibiotic suppression were categorized as improved rather than cured. Patients in whom soft tissue infections responded to ceftriaxone but who required amputation for underlying chronic osteomyelitis or vascular insufficiency were also classified as improved rather than cured.
The osteomyelitis in these cases was not evaluated for efficacy of the drug.
Four patients could not be evaluated for clinical efficacy. Two of these patients had pulmonary infiltrates but were not infected. One of these two had recurrent pulmonary emboli, and the other had pulmonary hemorrhage. Two other patients could not be assessed because they died within 36 h of initiation of therapy. One pg/mi).
Eight patients with pneumonia were cured by ceftriaxone therapy. Five of these patients were infected with Streptococcus pneumoniae, one was infected with Haemophilus influenzae, and two were infected with both S. aureus and a streptococcal species.
Two patients with biliary infections responded to ceftriaxone therapy. In one patient blood cultures were positive for Klebsiella pneumoniae. The other patient had a fever of 39.3°C and clinical and laboratory evidence of biliary obstruction, but negative blood cultures. This patient underwent a cholecystectomy after 1 week of therapy with ceftriaxone, at which time gall bladder cultures were sterile.
There was a single episode of sinusitis, which improved with resolution of fever and purulent drainage. A culture of the sinus revealed a mixed flora, including P. aeruginosa and S. marcescens. A case of diverticulitis with polymicrobial bacteremia also improved with ceftriaxone therapy, with resolution of fever, leukocytosis, and abdominal tenderness. Several weeks after discharge, the symptoms recurred, and a sigmoid resection confirmed the presence of a diverticular abscess. An intravenous drug abuser with a retroperitoneal abscess improved with ceftriaxone therapy and percutaneous drainage despite 
